Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 advanced discovery programs, and more than 10 partnered programs Platform will ...

KUALA LUMPUR, Oct 23 (Bernama) -- Recursion, a clinical stage TechBio company, announced the first patient has been dosed in its Phase 2 clinical trial of REC-3964, a potential first-in-class, oral ...

On Tuesday, TD Cowen maintained a Hold rating on shares of Recursion Pharmaceuticals (NASDAQ:RXRX) following the release of Phase 2 clinical trial data. The trial, which involved REC-994, a superoxide ...

SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...

Artificial intelligence (AI)-based drug developer Recursion has dosed the first patient in its Phase II ALDER trial (NCT06536465) assessing its first new chemical entity to be developed through its ...

A team led by Regina Barzilay, a computer science professor at the Massachusetts Institute of Technology, has launched Boltz-2, an algorithm that unites protein folding and prediction of ...

Chris Gibson, Cofounder and CEO of Recursion, lays out how his company is building the biological data, and layering on AI, to assist in the development of new, effective therapeutics.

I had a conference call with a potential client 2 days ago, with a 3rd party that is in the running for handling my potential client's cloud-based database management. During the call, they mentioned ...